Unknown

Dataset Information

0

Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia.


ABSTRACT: BACKGROUND:Despite the impressive complete remission (CR) induced by CD19 CAR-T cell therapy in B-ALL, the high rate of complete responses is sometimes limited by the emergence of CD19-negative leukemia. Bispecific CAR-modified T cells targeting both CD19 and CD22 may overcome the limitation of CD19-negative relapse. METHODS:We here report the design of a bispecific CAR simultaneous targeting of CD19 and CD22. We performed a phase 1 trial of bispecific CAR T cell therapy in patients with relapsed/refractory precursor B-ALL at a dose that ranged from 1.7 × 106 to 3 × 106 CAR T cells per kilogram of body weight. RESULTS:We demonstrate bispecific CD19/CD22 CAR T cells could trigger robust cytolytic activity against target cells. MRD-negative CR was achieved in 6 out of 6 enrolled patients. Autologous CD19/CD22 CAR T cells proliferated in vivo and were detected in the blood, bone marrow, and cerebrospinal fluid. No neurotoxicity occurred in any of the 6 patients treated. Of note, one patient had a relapse with blast cells that no longer expressed CD19 and exhibited diminished CD22 site density approximately 5?months after treatment. CONCLUSION:In brief, autologous CD19/CD22 CAR T cell therapy is feasible and safe and mediates potent anti-leukemic activity in patients with relapsed/refractory B-ALL. Furthermore, the emergence of target antigen loss and expression downregulation highlights the critical need to anticipate antigen escape. Our study demonstrates the reliability of bispecific CD19/CD22 CAR T cell therapy in inducing remission in adult patients with relapsed/refractory B-ALL. TRIAL REGISTRATION:ClinicalTrials.gov identifier: NCT03185494.

SUBMITTER: Dai H 

PROVIDER: S-EPMC7126394 | biostudies-literature | 2020 Apr

REPOSITORIES: biostudies-literature

altmetric image

Publications

Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia.

Dai Hanren H   Wu Zhiqiang Z   Jia Hejin H   Tong Chuan C   Guo Yelei Y   Ti Dongdong D   Han Xiao X   Liu Yang Y   Zhang Wenying W   Wang Chunmeng C   Zhang Yajing Y   Chen Meixia M   Yang Qingming Q   Wang Yao Y   Han Weidong W  

Journal of hematology & oncology 20200403 1


<h4>Background</h4>Despite the impressive complete remission (CR) induced by CD19 CAR-T cell therapy in B-ALL, the high rate of complete responses is sometimes limited by the emergence of CD19-negative leukemia. Bispecific CAR-modified T cells targeting both CD19 and CD22 may overcome the limitation of CD19-negative relapse.<h4>Methods</h4>We here report the design of a bispecific CAR simultaneous targeting of CD19 and CD22. We performed a phase 1 trial of bispecific CAR T cell therapy in patien  ...[more]

Similar Datasets

| S-EPMC8516648 | biostudies-literature
| S-EPMC10646794 | biostudies-literature
| S-EPMC7487702 | biostudies-literature
| S-EPMC9999039 | biostudies-literature
| S-EPMC9593019 | biostudies-literature
| S-EPMC6558895 | biostudies-literature
| S-EPMC8939233 | biostudies-literature
| S-EPMC11306243 | biostudies-literature
| S-EPMC4360883 | biostudies-literature